JERUSALEM, Israel, March 25, 2010 OramedPharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the completion of its'pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. TheCompany expects to report results from this study within the coming weeks.
The Phase 2b trial is a randomized, double-blind, placebo-controlled,multi-centered study, that primary evaluated the safety, and tolerability ofOramed's oral insulin delivery technology. The study took place in fivelocations throughout South Africa and was monitored by OnQ Consulting, aclinical research organization (CRO) based in Johannesburg, South Africa.
"The completion of the Phase 2b clinical trial for ORMD-0801 is asignificant milestone for Oramed," said Nadav Kidron, Chief Executive Officerof the Company, who continued, "We are especially thankful for the dedicationof all the investigators who participated in the study."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inPhase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research performed by top research scientists at Jerusalem'sHadassah Medical Center. The Company's corporate and R&D headquarters arebased in Jerusalem.
For more information, please visit http://www.oramed.com
Safe Harbor Statement
Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relation Contacts: Oramed Pharmaceuticals Tara Horn Office: 646-240-4193 Cell: +972-54-334-318 Email: firstname.lastname@example.org
SOURCE Oramed Pharmaceuticals Inc.